Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Completed · Phase 4

Conditions studied: Postmenopausal Osteoporosis

In brief

The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.

Key facts

Study ID

NCT01750086

Run by

Massachusetts General Hospital

People needed

27

Starts

2013-01-01

Expected to finish

2014-08-01

Last updated by the study team

2017-03-27

Who can join

Age: 45 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Must satisfy A and B and C below:
• A. Women aged 45+
• B. Postmenopausal
• C. Osteoporotic with high risk of fracture

You may not qualify if…

• History of significant hepatic, renal, cardiovascular, malignant disease, or conditions with impaired immune system
• Current alcohol or substance abuse
• Major psychiatric disorders
• Abnormal calcium level, elevated PTH, vitamin D deficiency, or anemia
• Known congenital or acquired bone disease other than osteoporosis
• Current use or past use in the past 12 months of oral bisphosphonates
• Current use or use in the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin
• Use of oral or parenteral glucocorticoids for more than 14 days in the past 6 months
• Any current or previous use of strontium or intravenous bisphosphonates
• Sensitivity to cell-derived drug products or teriparatide
• Extensive dental work involving dental extraction or dental implant within the past 2 months or in the upcoming 2 months
• Inability to sit upright for 30 minutes
• Esophageal abnormalities

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.